Clinical ResearchHeart Rhythm DisorderComparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score
Key Words
Abbreviations and Acronyms
Cited by (0)
The SPORTIF III and V studies were sponsored by AstraZeneca. Dr. Lip has received funding for research, educational symposia, consultancy, and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation and thrombosis, including AstraZeneca, Boehringer, Nayer, Pfizer/BMS, Biotronic, Astellas, Sanofi, Cardiome, and Merck; and is a clinical advisor to the UK NICE Guidelines on AF management, and a task force member of the 2010 ESC guidelines and ACCP9 writing committee. Dr. Frison is an employee of AstraZeneca. Dr. Halperin has received consulting fees from several pharmaceutical manufacturers involved in the development of novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation, including AstraZeneca, the sponsor of the SPORTIF trials. Dr. Lane has received an investigator-initiated educational grant from Bayer Healthcare, and has received sponsorship to attend meetings from AstraZeneca.